1115-P: Advanced Medical Therapy (AMT) for Youth-Onset Type 2 Diabetes (T2D)—Early Results from the Run-in Phase of ST2OMP
The Surgical or Medical Treatment for Pediatric Type 2 Diabetes (ST2OMP) study is a prospective open label clinical trial comparing metabolic bariatric surgery (MBS) to AMT for teens with youth-onset T2D. Prior to study group assignment, youth participate in a 6-month run-in period and receive AMT d...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2023-06, Vol.72 (Supplement_1), p.1 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | 1 |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 72 |
| creator | SHAH, AMY S. KELSEY, MEGAN M. JENKINS, TODD M. SCHAAF, LISA R. XANTHAKOS, STAVRA TROUT, ANDREW T. BAUMGARTNER, AMY RIEGLER, ALLEN KRISHNAN, NISHA BAILEY, ALEXANDER INGE, THOMAS HELMRATH, MICHAEL NADEAU, KRISTEN J. |
| description | The Surgical or Medical Treatment for Pediatric Type 2 Diabetes (ST2OMP) study is a prospective open label clinical trial comparing metabolic bariatric surgery (MBS) to AMT for teens with youth-onset T2D. Prior to study group assignment, youth participate in a 6-month run-in period and receive AMT defined as multidrug, treat-to-target medical therapy to achieve an HbA1c |
| doi_str_mv | 10.2337/db23-1115-P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2849360322</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2849360322</sourcerecordid><originalsourceid>FETCH-LOGICAL-c642-ab817d783826c1923416f6290f5cc4011405474c26cc6596903ab61f6c3df2dc3</originalsourceid><addsrcrecordid>eNotkM1Kw0AUhQdRsFZXvsAFNy0yOj_JJHFX2voDLQ01C12FyWSGtKRJnEmEggsfwif0SUyp3MVZ3I9z4EPompI7xnlwn2eMY0qpj-MTNKARjzBnwdspGhBCGaZBFJyjC-e2hBDR3wB9HekHmOSfslI6h6XON0qWkBTaymYPo8kyGYOpLbzXXVvgVeV0C8m-0cBgtpGZbrWDUcJm49_vn7m05R7W2nVl68DYegdtoWHdVXhTQVxIp6E28Jqw1TK-RGdGlk5f_ecQJY_zZPqMF6unl-lkgZXwGJZZSIM8CHnIhKIR4x4VRrCIGF8pj1DqEd8LPNV_lfAjEREuM0GNUDw3LFd8iG6OtY2tPzrt2nRbd7bqF1MWehEXhDPWU7dHStnaOatN2tjNTtp9Skl6sJse7KYHX2nM_wC9z2ke</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2849360322</pqid></control><display><type>article</type><title>1115-P: Advanced Medical Therapy (AMT) for Youth-Onset Type 2 Diabetes (T2D)—Early Results from the Run-in Phase of ST2OMP</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>SHAH, AMY S. ; KELSEY, MEGAN M. ; JENKINS, TODD M. ; SCHAAF, LISA R. ; XANTHAKOS, STAVRA ; TROUT, ANDREW T. ; BAUMGARTNER, AMY ; RIEGLER, ALLEN ; KRISHNAN, NISHA ; BAILEY, ALEXANDER ; INGE, THOMAS ; HELMRATH, MICHAEL ; NADEAU, KRISTEN J.</creator><creatorcontrib>SHAH, AMY S. ; KELSEY, MEGAN M. ; JENKINS, TODD M. ; SCHAAF, LISA R. ; XANTHAKOS, STAVRA ; TROUT, ANDREW T. ; BAUMGARTNER, AMY ; RIEGLER, ALLEN ; KRISHNAN, NISHA ; BAILEY, ALEXANDER ; INGE, THOMAS ; HELMRATH, MICHAEL ; NADEAU, KRISTEN J.</creatorcontrib><description>The Surgical or Medical Treatment for Pediatric Type 2 Diabetes (ST2OMP) study is a prospective open label clinical trial comparing metabolic bariatric surgery (MBS) to AMT for teens with youth-onset T2D. Prior to study group assignment, youth participate in a 6-month run-in period and receive AMT defined as multidrug, treat-to-target medical therapy to achieve an HbA1c <6.5%. Here, we examine the effects of AMT on metabolic parameters during run-in on the initial 51 participants. Participants in ST2OMP (57% female, 30% Black, 38% Hispanic, 25% White) were a mean age of 16.8 years, median diabetes duration 1.1 years, and median HbA1c 6.5% at screening (49% with HbA1c <6.5%). During run-in, metformin or pioglitazone use alone decreased (35.3% to 31.4%), as did insulin use (37.3% to 31.4%), while use of SGLT-2 inhibitors or GLP-1 agonists alone, or dual or triple therapy without insulin increased (21.6% to 31.4%). There was a small decrease in BMI, triglycerides and ALT, but a small increase in systolic and diastolic BP and total cholesterol, and decrease in HDL. At completion of run-in, 49% had an HbA1c of <6.5%. During a 6-month run-in period, AMT, using alternatives to insulin resulted in reduced need for insulin with favorable effects in some metabolic parameters, without worsening glycemic control. Full cohort recruitment and two-year follow-up in ST2OMP will determine the benefits of AMT vs. MBS.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db23-1115-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Cholesterol ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Gastrointestinal surgery ; GLP-1 receptor agonists ; High density lipoprotein ; Insulin ; Medical treatment ; Metabolism ; Metformin ; Pediatrics ; Pioglitazone ; Triglycerides</subject><ispartof>Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1</ispartof><rights>Copyright American Diabetes Association Jun 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>SHAH, AMY S.</creatorcontrib><creatorcontrib>KELSEY, MEGAN M.</creatorcontrib><creatorcontrib>JENKINS, TODD M.</creatorcontrib><creatorcontrib>SCHAAF, LISA R.</creatorcontrib><creatorcontrib>XANTHAKOS, STAVRA</creatorcontrib><creatorcontrib>TROUT, ANDREW T.</creatorcontrib><creatorcontrib>BAUMGARTNER, AMY</creatorcontrib><creatorcontrib>RIEGLER, ALLEN</creatorcontrib><creatorcontrib>KRISHNAN, NISHA</creatorcontrib><creatorcontrib>BAILEY, ALEXANDER</creatorcontrib><creatorcontrib>INGE, THOMAS</creatorcontrib><creatorcontrib>HELMRATH, MICHAEL</creatorcontrib><creatorcontrib>NADEAU, KRISTEN J.</creatorcontrib><title>1115-P: Advanced Medical Therapy (AMT) for Youth-Onset Type 2 Diabetes (T2D)—Early Results from the Run-in Phase of ST2OMP</title><title>Diabetes (New York, N.Y.)</title><description>The Surgical or Medical Treatment for Pediatric Type 2 Diabetes (ST2OMP) study is a prospective open label clinical trial comparing metabolic bariatric surgery (MBS) to AMT for teens with youth-onset T2D. Prior to study group assignment, youth participate in a 6-month run-in period and receive AMT defined as multidrug, treat-to-target medical therapy to achieve an HbA1c <6.5%. Here, we examine the effects of AMT on metabolic parameters during run-in on the initial 51 participants. Participants in ST2OMP (57% female, 30% Black, 38% Hispanic, 25% White) were a mean age of 16.8 years, median diabetes duration 1.1 years, and median HbA1c 6.5% at screening (49% with HbA1c <6.5%). During run-in, metformin or pioglitazone use alone decreased (35.3% to 31.4%), as did insulin use (37.3% to 31.4%), while use of SGLT-2 inhibitors or GLP-1 agonists alone, or dual or triple therapy without insulin increased (21.6% to 31.4%). There was a small decrease in BMI, triglycerides and ALT, but a small increase in systolic and diastolic BP and total cholesterol, and decrease in HDL. At completion of run-in, 49% had an HbA1c of <6.5%. During a 6-month run-in period, AMT, using alternatives to insulin resulted in reduced need for insulin with favorable effects in some metabolic parameters, without worsening glycemic control. Full cohort recruitment and two-year follow-up in ST2OMP will determine the benefits of AMT vs. MBS.</description><subject>Cholesterol</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Gastrointestinal surgery</subject><subject>GLP-1 receptor agonists</subject><subject>High density lipoprotein</subject><subject>Insulin</subject><subject>Medical treatment</subject><subject>Metabolism</subject><subject>Metformin</subject><subject>Pediatrics</subject><subject>Pioglitazone</subject><subject>Triglycerides</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNotkM1Kw0AUhQdRsFZXvsAFNy0yOj_JJHFX2voDLQ01C12FyWSGtKRJnEmEggsfwif0SUyp3MVZ3I9z4EPompI7xnlwn2eMY0qpj-MTNKARjzBnwdspGhBCGaZBFJyjC-e2hBDR3wB9HekHmOSfslI6h6XON0qWkBTaymYPo8kyGYOpLbzXXVvgVeV0C8m-0cBgtpGZbrWDUcJm49_vn7m05R7W2nVl68DYegdtoWHdVXhTQVxIp6E28Jqw1TK-RGdGlk5f_ecQJY_zZPqMF6unl-lkgZXwGJZZSIM8CHnIhKIR4x4VRrCIGF8pj1DqEd8LPNV_lfAjEREuM0GNUDw3LFd8iG6OtY2tPzrt2nRbd7bqF1MWehEXhDPWU7dHStnaOatN2tjNTtp9Skl6sJse7KYHX2nM_wC9z2ke</recordid><startdate>20230620</startdate><enddate>20230620</enddate><creator>SHAH, AMY S.</creator><creator>KELSEY, MEGAN M.</creator><creator>JENKINS, TODD M.</creator><creator>SCHAAF, LISA R.</creator><creator>XANTHAKOS, STAVRA</creator><creator>TROUT, ANDREW T.</creator><creator>BAUMGARTNER, AMY</creator><creator>RIEGLER, ALLEN</creator><creator>KRISHNAN, NISHA</creator><creator>BAILEY, ALEXANDER</creator><creator>INGE, THOMAS</creator><creator>HELMRATH, MICHAEL</creator><creator>NADEAU, KRISTEN J.</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20230620</creationdate><title>1115-P: Advanced Medical Therapy (AMT) for Youth-Onset Type 2 Diabetes (T2D)—Early Results from the Run-in Phase of ST2OMP</title><author>SHAH, AMY S. ; KELSEY, MEGAN M. ; JENKINS, TODD M. ; SCHAAF, LISA R. ; XANTHAKOS, STAVRA ; TROUT, ANDREW T. ; BAUMGARTNER, AMY ; RIEGLER, ALLEN ; KRISHNAN, NISHA ; BAILEY, ALEXANDER ; INGE, THOMAS ; HELMRATH, MICHAEL ; NADEAU, KRISTEN J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c642-ab817d783826c1923416f6290f5cc4011405474c26cc6596903ab61f6c3df2dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cholesterol</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Gastrointestinal surgery</topic><topic>GLP-1 receptor agonists</topic><topic>High density lipoprotein</topic><topic>Insulin</topic><topic>Medical treatment</topic><topic>Metabolism</topic><topic>Metformin</topic><topic>Pediatrics</topic><topic>Pioglitazone</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SHAH, AMY S.</creatorcontrib><creatorcontrib>KELSEY, MEGAN M.</creatorcontrib><creatorcontrib>JENKINS, TODD M.</creatorcontrib><creatorcontrib>SCHAAF, LISA R.</creatorcontrib><creatorcontrib>XANTHAKOS, STAVRA</creatorcontrib><creatorcontrib>TROUT, ANDREW T.</creatorcontrib><creatorcontrib>BAUMGARTNER, AMY</creatorcontrib><creatorcontrib>RIEGLER, ALLEN</creatorcontrib><creatorcontrib>KRISHNAN, NISHA</creatorcontrib><creatorcontrib>BAILEY, ALEXANDER</creatorcontrib><creatorcontrib>INGE, THOMAS</creatorcontrib><creatorcontrib>HELMRATH, MICHAEL</creatorcontrib><creatorcontrib>NADEAU, KRISTEN J.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SHAH, AMY S.</au><au>KELSEY, MEGAN M.</au><au>JENKINS, TODD M.</au><au>SCHAAF, LISA R.</au><au>XANTHAKOS, STAVRA</au><au>TROUT, ANDREW T.</au><au>BAUMGARTNER, AMY</au><au>RIEGLER, ALLEN</au><au>KRISHNAN, NISHA</au><au>BAILEY, ALEXANDER</au><au>INGE, THOMAS</au><au>HELMRATH, MICHAEL</au><au>NADEAU, KRISTEN J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1115-P: Advanced Medical Therapy (AMT) for Youth-Onset Type 2 Diabetes (T2D)—Early Results from the Run-in Phase of ST2OMP</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2023-06-20</date><risdate>2023</risdate><volume>72</volume><issue>Supplement_1</issue><spage>1</spage><pages>1-</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>The Surgical or Medical Treatment for Pediatric Type 2 Diabetes (ST2OMP) study is a prospective open label clinical trial comparing metabolic bariatric surgery (MBS) to AMT for teens with youth-onset T2D. Prior to study group assignment, youth participate in a 6-month run-in period and receive AMT defined as multidrug, treat-to-target medical therapy to achieve an HbA1c <6.5%. Here, we examine the effects of AMT on metabolic parameters during run-in on the initial 51 participants. Participants in ST2OMP (57% female, 30% Black, 38% Hispanic, 25% White) were a mean age of 16.8 years, median diabetes duration 1.1 years, and median HbA1c 6.5% at screening (49% with HbA1c <6.5%). During run-in, metformin or pioglitazone use alone decreased (35.3% to 31.4%), as did insulin use (37.3% to 31.4%), while use of SGLT-2 inhibitors or GLP-1 agonists alone, or dual or triple therapy without insulin increased (21.6% to 31.4%). There was a small decrease in BMI, triglycerides and ALT, but a small increase in systolic and diastolic BP and total cholesterol, and decrease in HDL. At completion of run-in, 49% had an HbA1c of <6.5%. During a 6-month run-in period, AMT, using alternatives to insulin resulted in reduced need for insulin with favorable effects in some metabolic parameters, without worsening glycemic control. Full cohort recruitment and two-year follow-up in ST2OMP will determine the benefits of AMT vs. MBS.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db23-1115-P</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1 |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_2849360322 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Cholesterol Diabetes Diabetes mellitus (non-insulin dependent) Gastrointestinal surgery GLP-1 receptor agonists High density lipoprotein Insulin Medical treatment Metabolism Metformin Pediatrics Pioglitazone Triglycerides |
| title | 1115-P: Advanced Medical Therapy (AMT) for Youth-Onset Type 2 Diabetes (T2D)—Early Results from the Run-in Phase of ST2OMP |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T20%3A20%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1115-P:%20Advanced%20Medical%20Therapy%20(AMT)%20for%20Youth-Onset%20Type%202%20Diabetes%20(T2D)%E2%80%94Early%20Results%20from%20the%20Run-in%20Phase%20of%20ST2OMP&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=SHAH,%20AMY%20S.&rft.date=2023-06-20&rft.volume=72&rft.issue=Supplement_1&rft.spage=1&rft.pages=1-&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db23-1115-P&rft_dat=%3Cproquest_cross%3E2849360322%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2849360322&rft_id=info:pmid/&rfr_iscdi=true |